Assess whether scientific advice should be sought before the next trial

SITUATION After a literature paper the 505(b)(2) package leans on getting retracted, advisory-committee question list that exposes a weak secondary endpoint is what regulatory-affairs lead can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a literature paper the 505(b)(2) package leans on getting retracted for regulatory-affairs lead. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision scientific advice should be turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move scientific advice should be for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.